Samsung Biologics Receives 'Leadership' Rating in Water Management from CDP Evaluation

Achieving Top Ratings in Major Global Sustainability Indicators

Samsung Biologics Plant 4 exterior. Photo by Samsung Biologics

Samsung Biologics announced on the 12th that it has received the top-tier 'Leadership' rating in the Water Security category from the Carbon Disclosure Project (CDP), a global sustainability management evaluation organization.

CDP, established in the UK in 2000, conducts projects requesting disclosure of information related to environmental issue responses from major listed companies worldwide. In 2024, over 24,800 companies participated.

The CDP evaluation is regarded as a major global sustainability indicator alongside the Dow Jones Sustainability Index (DJSI). Achieving a top rating requires balanced scores across various areas such as strategy, goals, and activities, thus earning high external credibility. Notably, major global big pharma companies like GlaxoSmithKline (GSK), AstraZeneca (AZ), and Novartis use it as an indicator to assess climate change response levels when selecting Contract Development and Manufacturing Organizations (CDMOs).

CDP ratings are assigned in order from Leadership (A- or A), Management (B- or B), Awareness (C- or C), to Disclosure (D- or D). Samsung Biologics received an A- rating in the Water Security category of the CDP evaluation, recognizing its global ESG (Environmental, Social, and Governance) leadership.

In this evaluation, Samsung Biologics was acknowledged for its excellent ESG capabilities through activities such as setting specific targets for natural capital strategy and water pollution management, water reuse rates, and ensuring the accuracy and reliability of water intake, discharge, and consumption data.

Beyond this, Samsung Biologics has been focusing company-wide efforts not only on expanding production capacity but also on ESG management to strengthen corporate competitiveness with the goal of becoming a 'Sustainable CDMO Partner.' Based on this, it has been included in the DJSI World Index, a major global ESG evaluation indicator, for four consecutive years.

In particular, Samsung Biologics is solidifying its global leadership in ESG by having CEO John Rim serve as the chair of the supply chain sector of the Health Systems Task Force (TF) within the Sustainable Markets Initiative (SMI), a major global initiative. Launched under the auspices of King Charles III of the UK after the 2020 World Economic Forum (WEF), SMI is a global climate change response initiative. CEO John Rim participates in the Health Systems TF alongside CEOs of major global big pharma companies such as GSK, AZ, Merck, Novo Nordisk, Roche, and Sanofi.

In 2023, Samsung Biologics was recognized for its efforts toward a sustainable future by receiving the 'Terra Carta Seal,' awarded only to companies presenting concrete and innovative roadmaps for carbon neutrality within the SMI.

John Rim, CEO of Samsung Biologics, stated, "We will continue efforts to strengthen ESG evaluations of the supply chain and operate a sustainable supply chain. As a global ESG leader, we will strive to be trusted by various stakeholders and contribute to a better future for humanity."